JPM vs NNY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NNY exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating poor fundamental momentum. However, as a municipal value fund, its valuation is best viewed through its Price-to-Book ratio of 1.00, suggesting it is trading exactly at its net asset value. While profitability metrics are negative and technical trends are bearish (0/100), the fund maintains a stable dividend yield of 4.14% and positive long-term price appreciation. The overall outlook is neutral, as the fund serves as an income vehicle rather than a growth equity.
Compare Another Pair
Related Comparisons
JPM vs NNY: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen New York Municipal Value Fund (NNY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.